In clinical phase I and II studies, it has been shown to significantly prolong progression-free (PFS) and overall survival (OS) in patients suffering from CLDN18.2-positive, HER2-negative locally advanced gastric cancer [12–14]. Here, ERBB2 is linked to gastric cancer.